Amundi launches Solana fund with €2.4T backing
Amundi and Spiko Finance launched the SAFO tokenised UCITS fund on the Solana blockchain, extending the fund to its eighth supported network.

Finance journalist at Grafa with years of experience covering Asia-Pacific financial markets at S&P Global, Mortgage Ezy, and GMA Network.
Amundi and Spiko Finance launched the SAFO tokenised UCITS fund on the Solana blockchain, extending the fund to its eighth supported network.
White Energy (ASX:WEC) has entered into a non-binding indicative term sheet for a series of proposed acquisitions and a capital raising initiative.
The Commodity Futures Trading Commission signed a memorandum of understanding with the National Hockey League to oversee sports-related prediction markets and combat insider trading and fraud.
Guzman y Gomez (ASX:GYG) announced an immediate exit from the United States market, shutting down its Chicago restaurants.
Preliminary negotiations reportedly have commenced between the Albanese Government and the Greens over contentious property tax legislation.
Hovnanian Enterprises (NYSE:HOV) reported a small net loss for its second fiscal quarter that nevertheless came in ahead of internal operating guidance, as resilient homebuyer traffic helped the national homebuilder mitigate ongoing margin compression and affordability hurdles.
HUTCHMED (NASDAQ:HCM) and Innovent Biologics jointly announced that China’s National Medical Products Administration has approved the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) for the treatment of adults with advanced kidney cancer.
Lightspeed Commerce (NYSE:LSPD) reported a 15% year-over-year revenue increase for its fourth fiscal quarter, capping a year marked by a strategic narrowing of its product portfolio and a return to positive adjusted cash generation.
Cato (NYSE:CATO) reported a substantial increase in its first-quarter net income for fiscal 2026, significantly bolstered by a millions-of-dollars tariff refund, even as management cautioned that macroeconomic pressures are weighing on its consumer base.
Eli Lilly (NYSE:LLY) announced historic topline results from its Phase 3 TRIUMPH-1 clinical trial, showing that its next-generation investigational drug, retatrutide, helped adults with obesity or overweight lose an average of up to 30.3% of their body weight.